Aesthetic Laser-Medical Devices Pipeline Assessment, 2017

Aesthetic Laser-Medical Devices Pipeline Assessment, 2017


  • Products Id :- GDME0342EPD
  • |
  • Pages: 94
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Aesthetic Laser-Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, "Aesthetic Laser-Medical Devices Pipeline Assessment, 2017" provides an overview of Aesthetic Laser currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Aesthetic Laser pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Aesthetic Laser under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Aesthetic Laser and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to-

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Aesthetic Laser under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product's current stage of development, territory and estimated launch date



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 5

2 Introduction 6

2.1 Aesthetic Laser Overview 6

3 Products under Development 7

3.1 Aesthetic Laser-Pipeline Products by Stage of Development 7

3.2 Aesthetic Laser-Pipeline Products by Territory 8

3.3 Aesthetic Laser-Pipeline Products by Regulatory Path 9

3.4 Aesthetic Laser-Pipeline Products by Estimated Approval Date 10

3.5 Aesthetic Laser-Ongoing Clinical Trials 11

4 Aesthetic Laser-Pipeline Products under Development by Companies 12

4.1 Aesthetic Laser Companies-Pipeline Products by Stage of Development 12

4.2 Aesthetic Laser-Pipeline Products by Stage of Development 13

5 Aesthetic Laser Companies and Product Overview 14

5.1 Cutera Inc Company Overview 14

5.1.1 Cutera Inc Pipeline Products & Ongoing Clinical Trials Overview 14

5.2 Erchonia Corp Company Overview 19

5.2.1 Erchonia Corp Pipeline Products & Ongoing Clinical Trials Overview 19

5.3 Eternity Healthcare Inc. Company Overview 20

5.3.1 Eternity Healthcare Inc. Pipeline Products & Ongoing Clinical Trials Overview 20

5.4 Medifirst Solutions Inc Company Overview 21

5.4.1 Medifirst Solutions Inc Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 Medixsysteme Company Overview 22

5.5.1 Medixsysteme Pipeline Products & Ongoing Clinical Trials Overview 22

5.6 PS Advanced Engineering Company Overview 24

5.6.1 PS Advanced Engineering Pipeline Products & Ongoing Clinical Trials Overview 24

5.7 Sienna Biopharmaceuticals Inc Company Overview 25

5.7.1 Sienna Biopharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 25

5.8 Sybaritic Inc Company Overview 26

5.8.1 Sybaritic Inc Pipeline Products & Ongoing Clinical Trials Overview 26

6 Aesthetic Laser- Recent Developments 27

6.1 May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 27

6.2 May 05, 2017: Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership 27

6.3 May 04, 2017: Olympus Extends Portfolio of EndoTherapy Solutions at DDW 28

6.4 May 01, 2017: Cutera Reports First Quarter 2017 Financial Performance 29

6.5 Apr 27, 2017: Zimmer Biomet Reports First Quarter 2017 Financial Results 30

6.6 Apr 20, 2017: Cutera Announces Preliminary Financial Results for First Quarter of 2017 and Planned Management Change 31

6.7 Apr 11, 2017: Low-Level Light Therapy Accelerates Hair Growth in Chemotherapy Patients 32

6.8 Apr 10, 2017: Medifirst Solutions Provides Update on International Sales 33

6.9 Mar 28, 2017: Synergy MedSales Introduces Newly FDA-Approved Forma-TK Lasers 33

6.10 Mar 01, 2017: Syneron Candela Unveils PicoWay at the 2017 American Academy of Dermatology (AAD) Annual Meeting 34

6.11 Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 34

6.12 Feb 15, 2017: Syneron Medical Reports Fourth Quarter 2016 Revenue of $82.9 Million and Full Year 2016 Revenue $298.1 Million 38

6.13 Feb 13, 2017: Cutera Reports Fourth Quarter and Full-Year 2016 Record Revenue and Financial Results 39

6.14 Feb 07, 2017: Cynosure Achieves Record Quarterly Revenue of $122.1 Million in the Fourth Quarter of 2016, Up 19 Percent Year-over-Year 40

6.15 Jan 31, 2017: Syneron Medical Strengthens Senior Management Team with Appointment of Chief Human Resources Officer 42

6.16 Jan 31, 2017: Zimmer Biomet Reports Fourth Quarter and Full-Year 2016 Financial Results 43

6.17 Jan 17, 2017: Medifirst Solutions to Present Its Time Machine Laser in Morocco and Dubai 44

6.18 Jan 17, 2017: Zimmer Biomet Announces Americas Leadership Transition 44

6.19 Jan 12, 2017: Zimmer Biomet Announces Resolution with DOJ and SEC Regarding Previously Disclosed Legacy Biomet FCPA Matters 45

6.20 Jan 10, 2017: Zimmer Biomet Announces Fourth Quarter and Full-Year 2016 Preliminary Sales Results 45

6.21 Jan 09, 2017: Cutera Names James A. Reinstein as its Next President and CEO 46

6.22 Jan 09, 2017: Cutera Announces Record Revenue and Preliminary Financial Results for Fourth Quarter and Full Year 2016 47

6.23 Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 47

6.24 Dec 14, 2016: Zimmer Biomet Update on Product Supply Matters and Responsive Statement on Recently Completed FDA Inspection 48

6.25 Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology 48

6.26 Dec 06, 2016: CUTERA Launches New PICO Genesis Treatment With enlighten 49

6.27 Nov 29, 2016: Cynosure Receives CFDA Clearance to Market the Icon Aesthetic System in China 50

6.28 Nov 22, 2016: Medifirst Solutions Appoints Bill White to Its Advisory Board 50

6.29 Nov 22, 2016: Medifirst Solutions appoints new advisory board member 51

6.30 Nov 21, 2016: Medifirst Solutions Announces Update on International Sales 51

6.31 Nov 17, 2016: Former Valeant Executive And Former Philidor Ceo Charged In Manhattan Federal Court For Illegal Fraud And Kickback Scheme 52

6.32 Nov 15, 2016: Cynosure Health Welcomes Three New Board Members 53

6.33 Nov 15, 2016: Quanta Aesthetic Lasers names CEO 54

6.34 Nov 09, 2016: Syneron Medical Reports Third Quarter 2016 Revenue of $71.5 Million 54

6.35 Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 56

6.36 Nov 07, 2016: Cutera Reports Record Third Quarter 2016 Results 59

6.37 Nov 03, 2016: Medifirst Solutions Announces Update Regarding International Sales and Operations 60

6.38 Nov 03, 2016: Cutera Elects J. Daniel Plants as Chairman of the Board 60

6.39 Nov 01, 2016: Cynosure Promotes Doug Delaney to Chief Commercial Officer 61

6.40 Oct 31, 2016: Zimmer Biomet Reports Third Quarter 2016 Financial Results 61

6.41 Oct 25, 2016: Cynosure Announces Record Third-Quarter Revenues; Revenues Increase 36 Percent from Prior Year to $106.4 Million 62

6.42 Oct 17, 2016: Medifirst Solutions Announces Update Regarding Sales and Operations 63

6.43 Oct 17, 2016: Syneron Medical Strengthens Senior Management Team 64

6.44 Oct 17, 2016: Syneron Medical Announces Preliminary Third Quarter 2016 Revenue 65

6.45 Oct 13, 2016: Aerolase Hires Prominent Laser Sales Executive as VP Sales to Accelerate Expansion 65

6.46 Oct 11, 2016: Cutera Announces Preliminary Record Third Quarter 2016 Revenue 66

6.47 Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 66

6.48 Sep 13, 2016: Medifirst Solutions Announces Shareholder Update 67

6.49 Sep 13, 2016: Cynosure to Name Stephen J. Webber as New Chief Financial Officer 67

6.50 Aug 30, 2016: Apira Science's iGrow Becomes First Wearable Laser Device to be Cleared by ANVISA in Brazil 68

6.51 Aug 30, 2016: Brazil Approves Apira's iGrow Wearable Laser Device 69

6.52 Aug 25, 2016: Medifirst Solutions Announces Engagement of International Monetary 69

6.53 Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 70

6.54 Aug 18, 2016: Cutera Announces Management Changes 71

6.55 Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 71

6.56 Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 72

6.57 Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 73

6.58 Aug 04, 2016: Syneron Medical Reports Second Quarter 2016 Revenue of $75.0 Million and Non-GAAP EPS of $0.09 75

6.59 Aug 01, 2016: Cutera Reports Second Quarter 2016 Results 77

6.60 Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 78

6.61 Jul 28, 2016: Zimmer Biomet Reports Second Quarter 2016 Financial Results 78

6.62 Jul 26, 2016: Cynosure Receives Approval to Market SculpSure in South Korea 79

6.63 Jul 26, 2016: Cynosure Reports Net Income of $6.3 Million on Record Sales of $110.3 Million for the Second Quarter of 2016 80

6.64 Jul 26, 2016: Medifirst Solutions to Update Shareholders on Corporate and Sales Strategy 81

6.65 Jul 25, 2016: Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Ultra-Short 785nm Wavelength 81

6.66 Jul 18, 2016: Medifirst Solutions Sets Pricing for Its Flagship Product 82

6.67 Jul 15, 2016: Medifirst Solutions Is Granted 510(k) FDA Clearance 83

6.68 Jul 13, 2016: Cynosure Receives Health Canada Authorization to Market SculpSure 83

6.69 Jul 05, 2016: Nail Fungus Sufferers Find Relief in New Laser Treatment 84

6.70 Jun 29, 2016: Medifirst Solutions Updates Shareholders on its FDA 510(K) Submission 84

6.71 Jun 23, 2016: Medifirst Solutions 510(k) Submission Has Been Accepted By The FDA 85

6.72 Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations 85

6.73 Jun 16, 2016: Medifirst Solutions Announces Successful Completion of Testing for the Time Machine Laser Series 86

6.74 Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director 86

6.75 Jun 07, 2016: Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results 87

6.76 May 26, 2016: Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller 88

6.77 May 25, 2016: Cynosure Announces Planned Retirement of Timothy W. Baker as President, Chief Financial Officer and Chief Operating Officer 89

6.78 May 24, 2016: Cynosure Receives FDA Clearance to Market New PicoSure Energy Delivery System for Tattoos and Pigmented Lesions 90

7 Appendix 91

7.1 Methodology 91

7.2 About GlobalData 94

7.3 Contact Us 94

7.4 Disclaimer 94

1.2 List of Figures

Figure 1: Aesthetic Laser-Pipeline Products by Stage of Development 7

Figure 2: Aesthetic Laser-Pipeline Products by Territory 8

Figure 3: Aesthetic Laser-Pipeline Products by Regulatory Path 9

Figure 4: Aesthetic Laser-Pipeline Products by Estimated Approval Date 10

Figure 5: Aesthetic Laser-Ongoing Clinical Trials 11

1.1 List of Tables

Table 1: Aesthetic Laser-Pipeline Products by Stage of Development 7

Table 2: Aesthetic Laser-Pipeline Products by Territory 8

Table 3: Aesthetic Laser-Pipeline Products by Regulatory Path 9

Table 4: Aesthetic Laser-Pipeline Products by Estimated Approval Date 10

Table 5: Aesthetic Laser-Ongoing Clinical Trials 11

Table 6: Aesthetic Laser Companies-Pipeline Products by Stage of Development 12

Table 7: Aesthetic Laser-Pipeline Products by Stage of Development 13

Table 8: Cutera Inc Pipeline Products & Ongoing Clinical Trials Overview 14

Table 9: enlighten 670nm Laser-Skin Rejuvenation-Product Status 14

Table 10: enlighten 670nm Laser-Skin Rejuvenation-Product Description 14

Table 11: enlighten 670nm Laser-Tattoo Removal-Product Status 15

Table 12: enlighten 670nm Laser-Tattoo Removal-Product Description 15

Table 13: Cutera Inc-Ongoing Clinical Trials Overview 16

Table 14: enlighten 670nm Laser-Skin Rejuvenation-Study of a Novel Laser for Skin Rejuvenation 17

Table 15: enlighten 670nm Laser-Tattoo Removal-An Open Label, Split-tattoo Study Comparing the Safety and Efficacy of the 670nm Picosecond Laser Versus the 755 nm Picosecond Laser for Tattoo Removal 18

Table 16: Erchonia Corp Pipeline Products & Ongoing Clinical Trials Overview 19

Table 17: Low Level Laser-Hair Restoration-Product Status 19

Table 18: Low Level Laser-Hair Restoration-Product Description 19

Table 19: Eternity Healthcare Inc. Pipeline Products & Ongoing Clinical Trials Overview 20

Table 20: Hand-held Laser Hair Removal Device-Product Status 20

Table 21: Hand-held Laser Hair Removal Device-Product Description 20

Table 22: Medifirst Solutions Inc Pipeline Products & Ongoing Clinical Trials Overview 21

Table 23: Green Laser-532 nm-Product Status 21

Table 24: Green Laser-532 nm-Product Description 21

Table 25: Medixsysteme Pipeline Products & Ongoing Clinical Trials Overview 22

Table 26: SpaShape-Product Status 22

Table 27: SpaShape-Product Description 22

Table 28: Ultracontour-U.Lift-Product Status 23

Table 29: Ultracontour-U.Lift-Product Description 23

Table 30: PS Advanced Engineering Pipeline Products & Ongoing Clinical Trials Overview 24

Table 31: Panelized Anti Wrinkle Platform-Product Status 24

Table 32: Panelized Anti Wrinkle Platform-Product Description 24

Table 33: Sienna Biopharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 25

Table 34: Silver Plasmonic Therapy (SPT) Device-Light Hair Removal-Product Status 25

Table 35: Silver Plasmonic Therapy (SPT) Device-Light Hair Removal-Product Description 25

Table 36: Sybaritic Inc Pipeline Products & Ongoing Clinical Trials Overview 26

Table 37: SkinClear SRVH-Product Status 26

Table 38: SkinClear SRVH-Product Description 26

Table 39: Glossary 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Cutera Inc, Erchonia Corp, Eternity Healthcare Inc., Medifirst Solutions Inc, Medixsysteme, PS Advanced Engineering, Sienna Biopharmaceuticals Inc, Sybaritic Inc

Cutera Inc, enlighten 670nm Laser-Skin Rejuvenation; Cutera Inc, enlighten 670nm Laser-Tattoo Removal; Erchonia Corp, Low Level Laser-Hair Restoration; Eternity Healthcare Inc., Hand-held Laser Hair Removal Device; Medifirst Solutions Inc, Green Laser-532 nm; Medixsysteme, SpaShape; Medixsysteme, Ultracontour-U.Lift; PS Advanced Engineering, Panelized Anti Wrinkle Platform; Sienna Biopharmaceuticals Inc, Silver Plasmonic Therapy (SPT) Device-Light Hair Removal; Sybaritic Inc, SkinClear SRVH

select a license

Single User License
USD 2500 INR 162350
Site License
USD 5000 INR 324700
Corporate User License
USD 7500 INR 487050

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com